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Aims. We sought to determine the association between levels of adiponectin and oxidized low-density lipoprotein (ox-LDL) in
patients with diabetic nephropathy as well as their effect on carotid intima-media thickness (cIMT). Methods. Adiponectin and
ox-LDL were determined in 25 diabetic patients without nephropathy and 94 patients at different stages of diabetic nephropathy
including subjects on hemodialysis. cIMT was measured using real-time B-mode ultrasonography. Results. Plasma adiponectin
levels increased significantly with severity of diabetic nephropathy (𝑃 = 0.002), on the contrary to ox-LDL which decreased with
disease severity (𝑃 < 0.001). cIMT was significantly higher at late stages of diabetic nephropathy compared with early stages (𝑃 =
0.022). Adiponectin was a significant negative predictor of ox-LDL levels (𝛽 = −5.45, 𝑃 = 0.023), independently of confounding
factors. There was no significant correlation between cIMT and adiponectin or ox-LDL either in the total sample population or
according to disease staging. Cluster analysis showed that patients with the highest cIMT values, highest levels of adiponectin, and
lowest levels of ox-LDL were included in one cluster and all assigned to stage 5 of diabetic nephropathy. Conclusions. There was no
significant association between adiponectin or ox-LDL and cIMT and, therefore, other factors affecting this surrogate marker of
cardiovascular disease in diabetic nephropathy should be sought.
1. Introduction
Diabetic nephropathy is a complex disease affecting approxi-
mately 30% of patients with type 2 diabetes mellitus (T2DM)
[1] and leading to increased morbidity and mortality. The
pathogenesis of diabetic nephropathy is multifactorial; how-
ever, the mechanisms that drive its development remain
largely undetermined [2, 3]. During the course of dia-
betic nephropathy, the functional impairment and structural
remodeling of the kidney, induced by hyperglycemic injury,
are linked to changes in several cellular events and activation
of signaling pathways.
Adipokines, including adiponectin, exert regulatory ac-
tivities on various target tissues. Most clinical and experi-
mental studies support a controversial role of adiponectin in
diabetic nephropathy. Adiponectin-knockout (Ad−/−) mice
exhibited increased albuminuria and fusion of podocyte
foot processes, whereas infusion of adiponectin reduced
oxidative stress and reversed the albuminuria [4]. However,
the beneficial roles of adiponectin may not be completely
applied to the entire course of diabetic nephropathy. In
early diabetic nephropathy, endothelial dysfunction is asso-
ciated with low circulating adiponectin [5]. Nevertheless, in
advanced diabetic nephropathy with macroalbuminuria or
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renal insufficiency, increased serum adiponectin levels were
observed [6–8], predicting coexisting vascular endothelial
dysfunction [6]. In addition, high serum adiponectin levels
predict mortality and progression to end stage renal disease
in type I diabetic patients [9]. The discrepancy between
beneficial effects of adiponectin, observed mainly in early
diabetic nephropathy, and association of adiponectin with
negative prognosis in diabetic and nondiabetic patients with
more advanced chronic kidney disease (CKD) is generally
explained by the confounding effect of inflammation of CKD
and dialysis which at the same time impacts on prognosis and
triggers increased adiponectin synthesis [10, 11]. Moreover,
the expected inverse relationship between adiponectin and
clinical outcomes may be modified by differential retention
of high-molecular weight forms of adiponectin in renal
failure, the nutritional and inflammatory status, adiponectin
gene polymorphisms, and combination of these factors
[12].
The role of lipid abnormalities in the pathogenesis of
glomerular injury has been demonstrated in animal models
in addition to a link between hypercholesterolemia and
diabetic nephropathy in humans [13]. Localized tissue oxida-
tive stress plays a key role in the development of diabetic
nephropathy [14] and oxidized low-density lipoprotein (ox-
LDL) is induced in the onset of the disease [15]. Elevated
plasma ox-LDL levels were observed in T2DM patients
with macroalbuminuria [16], whereas significantly lower
levels of ox-LDL were observed in CKD patients undergo-
ing hemodialysis compared with controls [17]. Decreased
adiponectin levels are an indicator of increased oxidative
state in the arterial wall, whereas adiponectin treatment
markedly suppresses foam cell formation in ox-LDL-treated
macrophages from diabetic subjects [18]. An inverse associ-
ation between adiponectin and ox-LDL levels was found in
T2DM patients with coronary artery disease [19] as well as
in hemodialysis patients [17]. However, the interplay between
adiponectin and ox-LDL levels has not been studied in
patients at different stages of diabetic nephropathy.
Although circulating adiponectin has been suggested as
a possible marker of cardiovascular disease in the general
population, it is a poor predictor of cardiovascular risk in
both the CKD and renal transplant population [20]. Non-
invasive techniques are widely used to estimate the stage of
atherosclerotic changes and carotid intima-media thickness
(cIMT) is a useful marker of diabetic macroangiopathy as
well as the extent of coronary artery disease in patients with
impaired renal function [21]. Findings on the association
between adiponectin levels and cIMT in kidney disease
are contradictory. In predialysis CKD patients, an inverse
association or no association was shown [22, 23]. Similarly,
in end stage renal disease, adiponectin was shown either to
correlate inverselywith cIMT [24] or not to be associatedwith
cIMT [25]. On the contrary, a positive correlation between
cIMT and adiponectin has been reported in patients with
diabetic nephropathy [6].
In the present study, we sought to explore (a) the associa-
tion between circulating levels of adiponectin and ox-LDL in
patients with diabetic nephropathy and (b) their association
with cIMT in the studied subjects.
2. Methods
2.1. Subjects. A total of 119 unrelated patients of Caucasian
originwere included in the study.The criteria for determining
subjects with T2DM for inclusion in the study have been
described before [26]. All eligible patients who consented to
participate in the study had to have a documented history of
type 2 diabetes for at least 10 years.
Established diabetic nephropathywas defined bymicroal-
buminuria (30–300mg/g creatinine) or persistent albumin-
uria (>300mg/g creatinine) in two out of three consecutive
measurements in sterile spot urine sample during a 6-
month period, presence of diabetic retinopathy, and absence
of other kidney or urinary tract disease [27, 28]. Diabetic
retinopathy (DR) was included in the eligibility criteria for
this study, since it is frequent in the presence of diabetic
nephropathy and is a clue for its diagnosis. DR was assessed
by fundoscopy, after pupillary dilatation.The ophthalmologic
exam result was classified as normal, nonproliferative, and
proliferative retinopathy. Patients were considered to have
DR if they showed nonproliferative or proliferative stage.
Alternatively, the patients might have a history of retinal
laser surgery (photocoagulation) for DR. The diagnosis and
classification of CKD stages were established according to
the criteria from the Clinical Practice Guidelines for Chronic
Kidney Disease from the National Kidney Foundation—
Kidney Disease Outcomes Quality Initiative [29]. Absence
of diabetic nephropathy (controls) was defined as absence of
diabetic retinopathy, eGFR above 60mL/min, and persistent
normoalbuminuria (0–30mg/g creatinine) after at least 10
years of type 2 diabetes. Patients with clinical or laboratory
evidence of nondiabetic nephropathy or urinary tract disease
were excluded from the study. All stage 5 CKD patients had
been under regular hemodialysis, for at least 6 months, and
were dialyzed thrice weekly for 4 hours per session (CKD-
5D).
All diabetic patients were regular patients at the Diabetes
Clinic and Nephrology Clinic of Academic General Hospital
of Alexandroupolis (Greece) and gave written informed
consent. The study was approved by the Ethics Committee
of the Scientific Council of the University General Hospital
of Alexandroupolis and was in accordance with Helsinki
Declaration of Human Rights.
2.2. LaboratoryMethods. Fasting bloodwas obtained fromall
patients and plasma was stored at −20∘C until analysis. Blood
samples were collected from hemodialysis patients after an
overnight fasting of 8 h, immediately before the start of a
routine 4 h hemodialysis session, as described in previous
studies [17, 30]. Blood was drawn from all patients into
EDTA-containing tubes and into tubes without anticoagulant
in order to obtain plasma, whole blood, and serum. Samples
for fasting blood glucose levels, HbA1c, total cholesterol,
low-density lipoprotein cholesterol (LDL-cholesterol), high-
density lipoprotein cholesterol (HDL-cholesterol), triglyc-
erides, and creatinine were transferred to the laboratory
and assayed immediately. For adiponectin and ox-LDL, the
samples were centrifuged immediately and plasmawas stored
at −20∘C until analysis.
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According to guidelines of American clinical practice
(K/DOQI), the five stages of renal insufficiency based on
eGFR are as follows: I ≥ 90, II = 60–89, III = 30–59, IV = 15–
29, and V < 15 [9, 31]. The glomerular filtration rate (GFR)
was estimated (eGFR) using the chronic kidney disease epi-
demiology collaboration (CKD-EPI) equation, which ismore
accurate and less biased than the MDRD Study equation,
especially in patients with higher GFR, resulting in reduced
misclassification of CKD [32].
Plasma concentrations of total adiponectin and ox-LDL
were quantitated by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (hu-
man adiponectin ELISA kit, Buhlmann, Switzerland; human
ox-LDL ELISA kit, Mercodia, Sweden). According to the
manufacturers, the detection limits for adiponectin and ox-
LDL assays were 0.08 ng/mL and 0.3U/L, respectively. Intra-
and interassay coefficients of variation were <15% and <10%
for adiponectin and ox-LDL, respectively.
2.3. Measurement of cIMT. Measurements of cIMT were
obtained from 117 out of 124 patients with diabetic nephropa-
thy recruited in this study. cIMT was considered the distance
from the leading edge of the lumen-intima interface to the
leading edge of the intima-adventitia interface. Measure-
ments of cIMT were performed online by a single trained
sonographer, using a high resolution, real-time ultrasono-
graph with a 7,5MHz transducer (ATL Ultrasound HDI
1300, Philips, Bothell, WA, USA). Three measurements were
performed for each of the common carotid arteries at 0.5,
1, and 1.5 cm distance from carotid bulb and mean cIMT
was calculated by averaging the sixmeasurements.Maximum
cIMTwas defined as the greatest value of those measurement
points of both sides.
2.4. Statistical Analysis. Statistical analyses were performed
using the Statistical Package for Social Sciences (SPSS 18.0
for Windows). Data for patients with diabetic nephropathy
at stages 3 and 4 were merged for analysis due to the
small number of subjects at stage 4 of the disease. Data
were tested for normality by Kolmogorov-Smirnov test.
Normally distributed continuous variables are presented as
mean (S.D.), whereas nonnormally distributed continuous
variables are presented as median (range). Comparisons
for normally distributed continuous variables among stages
of diabetic nephropathy were performed with one-way
ANOVA.Nonnormally distributed continuous variableswere
compared by Mann-Whitney test or Kruskal-Wallis test as
appropriate, whereas categorical variables were compared
by 𝜒2 test. Bivariate associations between variables were
examined using Spearman’s correlation coefficient. Correla-
tion analysis of cIMT with various factors (age, sex, body
mass index (BMI), systolic blood pressure, smoking, eGFR,
LDL-cholesterol, HDL-cholesterol, duration of T2DM, and
statin treatment) was conducted on an exploratory basis to
determine possible predictors of cIMT. Stepwise multiple
regression analysis was performed to study the relationship
between ox-LDL and adiponectin, adjusting for confounding
variables (LDL-cholesterol, triglycerides, and eGFR). The
same type of analysis was used to assess the significance of
possible predictors of cIMT (log-transformed) as determined
by correlation analysis. Cluster analysis methods lead to the
definition of groups with similar values of certain attributes
such as laboratory variables (qualitative or quantitative ana-
lytes) or other variables (e.g., anthropometric) [33]. Using
a matrix of distance measurements, cluster analysis finds
groups of subjects more similar to each other than to those
in other groups. The SPSS TwoStep cluster analysis is an
algorithm that finds the optimal number of clusters using
both continuous and categorical variables. In the present
model, age, fasting glucose, adiponectin, and ox-LDL were
included as continuous variables, whereas stage of diabetic
nephropathywas included as categorical variable. Differences
were considered statistically significant at a 𝑃 value of <0.05.
3. Results
Anthropometric, biochemical, and clinical data of patients
with diabetic nephropathy in total and according to stages
of disease are presented in Table 1. There was no significant
difference in age and the proportion of sexes across categories
of diabetic nephropathy severity. The duration of T2DM was
significantly different across groups and increased in late
stages of diabetic nephropathy (𝑃 = 0.01). Although total
cholesterol and LDL-cholesterol did not differ significantly
among groups, HDL-cholesterol decreased whereas triglyc-
erides increased with disease progression (𝑃 < 0.001 and
𝑃 = 0.006, resp.). Plasma adiponectin increased significantly
with disease severity (𝑃 = 0.002). Post hoc analysis showed
significant differences between control subjects and subjects
with stage 5 diabetic nephropathy (𝑃 = 0.002). Moreover,
significant differences were observed between subjects with
(a) stages 1/2 and 3/4 (𝑃 = 0.027), (b) stages 1/2 and
5 (𝑃 = 0.001), and (c) stages 3/4 and 5 (𝑃 = 0.048).
Conversely, circulating ox-LDL decreased significantly with
disease severity (𝑃 < 0.001). Post hoc analysis showed that
this was due to a difference between control subjects and
subjects with stage 5 diabetic nephropathy (𝑃 = 0.002) as
well as between subjects with stage 3/4 and stage 5 (𝑃 =
0.001). In addition, the ratio of ox-LDL/LDL-cholesterol
(U/mg) did not differ among groups (results not shown).
We also investigated the effect of angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers,metformin,
and statins on adiponectin and ox-LDL levels. The only
difference identified for adiponectin was that patients on
metformin (𝑁 = 35) had significantly lower levels of
adiponectin compared with those not taking the drug (6.1
versus 9.2 𝜇g/mL, 𝑃 = 0.001). Moreover, there was an effect
of statins on ox-LDL levels, as these were significantly lower
in patients (𝑁 = 95) treated with statins compared with
levels in untreated patients (59.1 versus 68.9U/L, 𝑃 = 0.04).
Finally, cIMTwas significantly higher at late stages of diabetic
nephropathy compared with control subjects (𝑃 = 0.022).
The latter had significantly lower cIMT values compared with
patients at stage 3/4 or 5 (𝑃 = 0.009 and 𝑃 = 0.017, resp.).
Table 2 shows the correlationmatrix between adiponectin
and ox-LDL with several characteristics of the patients stud-
ied. There was a significant inverse association between
adiponectin and ox-LDL in the total sample population
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Table 1: Anthropometric, clinical, and biochemical characteristics of patients with type 2 diabetes in the absence or presence of nephropathy
at different stages. Results for continuous variables are presented as mean (S.D.) or median (range).
Stage of diabetic nephropathy
𝑃
a
Control 1 & 2 3 & 4 5
𝑁 25 22 42 30
Age (y) 64.0 (7.1) 67.5 (8.8) 69.4 (8.2) 69.1 (9.7) 0.07
Gender (M/F) 8/17 3/13 25/17 13/17 0.14
BMI (kg/m2) 31.9 (6.6) 30.5 (4.1) 32.3 (4.8) 29.4 (5.2) 0.10
Duration of T2DM (y) 10.8 (5.8) 13.7 (7.0) 16.9 (9.0) 16.0 (6.6) 0.01
Fasting glucose (mg/dL) 151.8 (38.1) 148.8 (43.9) 159.0 (49.2) 189.4 (99.7) 0.07
HbA1c (%) 7.4 (1.0) 7.1 (0.8) 7.8 (1.4) 7.3 (0.9) 0.10
eGFR (mL/min/1.73m2) 86.2 (14.3) 77.7 (12.7) 38.4 (11.2) 7.0 (3.0) <0.001
Total cholesterol (mg/dL) 184.8 (51.6) 174.4 (37.5) 181.1 (43.8) 159.5 (47.7) 0.15
LDL-cholesterol (mg/dL) 101.3 (42.4) 98.1 (34.5) 101.0 (33.4) 87.0 (42.0) 0.41
HDL-cholesterol (mg/dL) 48.0 (11.3) 52.6 (16.5) 45.3 (10.2) 37.5 (9.6) <0.001
Triglycerides (mg/dL) 115.0 (52–292) 139.5 (53–320) 170.0 (59–450) 170.5 (61–551) 0.006
Plasma adiponectin (𝜇g/mL) 5.8 (2.2–12.4) 4.2 (2.4–36.5) 6.2 (2.0–38.8) 7.9 (3.2–43.2) 0.002
ox-LDL (U/L) 67.5 (21.5) 59.7 (17.3) 66.6 (17.4) 49.2 (16.3) <0.001
Mean cIMT (mm) 0.81 (0.55–1.61) 0.86 (0.61–1.25) 0.92 (0.66–1.78) 0.93 (0.60–1.45) 0.022
Maximum cIMT (mm) 0.85 (0.60–1.65) 1.00 (0.65–1.30) 1.00 (0.70–1.80) 1.00 (0.65–1.50) 0.021
a
𝑃 values of ANOVA or Kruskal-Wallis test for differences of variables among diabetic nephropathy stage groups.
Table 2: Correlation matrix between adiponectin, ox-LDL, and several characteristics of patients with type 2 diabetes in the absence or
presence of nephropathy at different stages. Values represent Spearman’s correlation coefficients.
ox-LDL Age BMI Glucose eGFR LDL-cholesterol HDL-cholesterol Triglycerides
Adiponectin −0.29b 0.26b −0.21a −0.14 −0.33b −0.07 0.09 −0.11
ox-LDL 1 −0.02 0.12 0.05 0.20a 0.48b 0.08 0.32b
aCorrelation is significant at the 0.05 level.
bCorrelation is significant at the 0.01 level.
(𝑟 = −0.29, 𝑃 < 0.01) as well as in different stages of diabetic
nephropathy (results not shown). Moreover, adiponectin
positively correlated with age, whereas it inversely correlated
with eGFR and BMI. However, there was no significant
correlation between adiponectin and glucose or lipids. A sig-
nificant positive association was observed between ox-LDL
and lipids/eGFR. After adjustment for age and BMI, plasma
adiponectin positively correlated with stages of diabetic
nephropathy (𝑟 = 0.23, 𝑃 = 0.014). Also, after adjustment
for LDL-cholesterol and triglycerides, ox-LDL was inversely
correlated with stages of diabetic nephropathy (𝑟 = −0.33,
𝑃 < 0.001). In multiple regression analysis (Table 3) includ-
ing the variables which correlated with ox-LDL (adiponectin,
eGFR, LDL-cholesterol, and triglycerides), adiponectin was a
significant negative predictor of ox-LDL levels (𝛽 = −5.02,
𝑃 = 0.049), independently of LDL-cholesterol, triglycerides,
and eGFR.
There was no significant correlation between cIMT and
adiponectin or ox-LDL either in the total sample population
(𝑟 = 0.14, 𝑃 = 0.13 and 𝑟 = −0.003, 𝑃 = 0.97, resp.) or in
any stage of diabetic nephropathy (results not shown). cIMT
significantly correlated with age (𝑟 = 0.24, 𝑃 = 0.008),
sex (𝑟 = −0.32, 𝑃 = 0.001), eGFR (𝑟 = −0.23, 𝑃 =
0.004), and HDL-cholesterol (𝑟 = −0.18, 𝑃 = 0.049). Also,
cIMT was significantly lower in patients treated with statins
Table 3: Regression coefficients (𝛽) of multiple regression models
with dependent variables ox-LDL or cIMT and independent vari-
ables selected based on respective associations.
𝛽 Standard error 𝑃
Model for ox-LDL
Adiponectin −5.02 2.5 0.049
eGFR 0.12 0.05 0.025
Triglycerides 0.06 0.02 0.004
LDL-cholesterol 0.20 0.05 0.025
Model for cIMTa
eGFR −0.002 0.001 0.003
Sex −0.102 0.042 0.017
aAge, statin treatment, and HDL-cholesterol were excluded from model.
compared with untreated patients (0.92mm versus 1.00mm,
𝑃 = 0.04). Inmultiple regression analysis including the above
variables (Table 3), the only independent predictors of cIMT
were eGFR (𝛽 = −0.002, 𝑃 = 0.003) and sex (𝛽 = −0.102,
𝑃 = 0.017).
Cluster analysis was performed to further explore the
interrelationship of adiponectin, ox-LDL, and cIMT regard-
ing the stage of diabetic nephropathy (Table 4). Based on four
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Table 4: Cluster profiles of subgroups of patients with diabetic nephropathy at different stages.
DN stage Age (y) cIMT (mm) Adiponectin (𝜇g/mL) ox-LDL (U/L) Cluster
1 2 3 4
Controls 64.0 (7.1) 0.83 (0.22) 6.1 (2.9) 67.5 (21.5) 25
1/2 67.2 (8.9) 0.87 (0.18) 4.9 (2.3) 60.4 (17.5) 21 1
3/4 69.4 (8.1) 0.98 (0.25) 9.0 (8.2) 66.1 (17.4) 42
5 68.8 (9.3) 0.95 (0.17) 9.5 (6.9) 52.5 (17.2) 23

















Figure 1: Within cluster percent of patients according to the stage
of diabetic nephropathy.
variables entered in the model (adiponectin, ox-LDL, cIMT,
and age), four clusters were formed, each one distinctively
characterizing each stage of diabetic nephropathy. Patients
with the highest cIMT values, highest levels of adiponectin,
and lowest levels of ox-LDL were included in cluster 3 and
all assigned to stage 5 of diabetic nephropathy. Conversely,
patients with the lowest cIMT values and low levels of
adiponectin were included in cluster 4 and all assigned to
the control group. Figure 1 shows within cluster percent of
patients according to the stage of diabetic nephropathy.
4. Discussion
In patients with diabetes mellitus as well as in those with
CKD, cardiovascular disease is the leading cause of mortality.
The increased cardiovascular disease risk cannot solely be
explained by traditional risk factors and, therefore, iden-
tification of novel modifiable risk factors is important in
preventing cardiovascular disease in diabetic nephropathy.
In the present study, we assessed circulating adiponectin
and ox-LDL levels in patients with diabetic nephropathy as
well as cIMT as a noninvasive surrogate of atherosclerotic
status. Plasma adiponectin levels increased significantly with
disease severity, in agreement with previous studies [7, 8].
Moreover, adiponectin positively correlated with age and
stages of diabetic nephropathy, whereas it inversely correlated
with eGFR and BMI, as previously observed [7]. Several
features of uremia, such as inflammation, oxidative stress,
and sympathetic overactivity, may decrease adiponectin
expression, whereas other features, such as decreased renal
function, proteinuria, and protein energy wasting, may
increase circulating adiponectin levels [34]. It is controversial
whether adiponectin levels are increased in chronic kidney
disease as a result of declining GFR and, therefore, decreased
catabolism or in response to other uremic factors, since
patients with advanced diabetic nephropathy have both
increased adiponectin serum concentrations and increased
urinary excretion [35]. It has been suggested that increased
adiponectin levels in overt diabetic nephropathy might be
a physiological response to counteract renal tubular injury
preventing the further progression of diabetic nephropathy
through its anti-inflammatory and antiatherogenic effects
[36]. It was recently shown that renal tubular cells secrete
adiponectin which increases upon inflammatory stimulus
[37] and, therefore, may contribute to the increase in circu-
lating adiponectin levels observed in diabetic nephropathy.
We found that patients taking metformin have lower levels
of plasma adiponectin. However, this is probably not a
real effect of metformin on adiponectin levels but can be
explained by the fact that this oral hypoglycemic agent is
contraindicated in patients with advanced kidney disease
due to the risk for lactic acidosis. The Canadian Diabetes
Association practice guidelines recommend that metformin
should be stopped when the patient has progressed to stage
4 CKD (GFR < 30mL/min/1.73m2) and should be used with
extreme caution in stage 3 CKD patients (GFR between 30
and 59mL/min/1.73m2) [38, 39]. In the present study, the
groups of patients under metformin therapy were control
patients without nephropathy, patients in stages 1 and 2, and
only the minority of patients (4 out of 35) in stage 3 CKD.
Therefore, the difference in adiponectin levels according to
metformin treatment seems to be due to confounding by its
restricted administration in late stages of CKD.
Plasma ox-LDL levels were significantly decreased in
patients with end stage diabetic nephropathy compared with
early stages. Despite the fact that some studies have reported
higher ox-LDL levels in patients undergoing hemodialy-
sis, contradicting results have also been reported. Some
authors found no difference between hemodialysis patients
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and controls [30, 40], whereas others described low ox-
LDL levels in these patients [17, 41–43]. Possible causes
of these contradictory results may be differences among
study populations in age, serum lipids, or disease since most
of the studies that reported elevated levels of ox-LDL in
hemodialysis patients compared ox-LDL levels in nondia-
betic end stage renal disease patients under hemodialysis
versus healthy controls. In the present study, we assessed ox-
LDL levels in diabetic patients in different stages of CKD
(stages 1–4), diabetic patients under hemodialysis (stage 5),
and diabetic controls without kidney failure. Although there
are reports with contradictory results on several markers
of oxidative stress in patients with end stage renal disease,
our results are in agreement with previous studies using the
same quantitation method for ox-LDL [17, 41, 42]. Since
the ratio of ox-LDL/LDL-cholesterol did not differ among
groups of patients, the proportion of LDL that is oxidized
was similar across different stages of diabetic nephropathy.
The reduction in ox-LDL levels in patients with end stage
diabetic nephropathy does not necessarily imply a reduced
risk of atherosclerosis. This could be due to a greater capture
of ox-LDL by macrophage scavenger receptors which are
increased in hemodialysis patients [42]. It is also likely that
decreased ox-LDL levels in hemodialysis patients are due to
a reduction in LDL particles [17]. Finally, Sevinc Ok et al.
reported that ox-LDL is not associated with the progres-
sion of atherosclerosis or cardiovascular/overall mortality in
hemodialysis patients [44].
It has been shown that low serum adiponectin is associ-
ated with high circulating oxidized low-density lipoprotein
in patients with type 2 diabetes mellitus and coronary artery
disease [19]. Similarly, we have shown an inverse association
between plasma levels of adiponectin and ox-LDL in the
total sample population as well as in different stages of
diabetic nephropathy. In the study by Lautamäki et al. [19],
adiponectin was an independent negative predictor of ox-
LDL but not lipids, whereas in the study by Ribeiro et al. [17]
independent associations of ox-LDL were found with lipids
but not adiponectin in patients under hemodialysis. Nev-
ertheless, in the present study, both lipids and adiponectin
were independent predictors of ox-LDL. It has been recently
shown that higher levels of adiponectin are associated with
a more beneficial oxidative stress profile and lower levels of
lipid peroxidation [45].
In patients with T2DM, increased cIMT was shown
to be partly explained by lower plasma adiponectin [46].
However, in patients with diabetic nephropathy, adiponectin
was shown to be associated with several indices of vascular
dysfunction, including a positive correlation with cIMT,
while increased plasma adiponectin was assumed to be
compensatory for early vascular endothelial damage [6].
We did not detect a significant association between cIMT
and adiponectin either in the total sample population or
according to disease staging, probably due to differences
in patient characteristics between our study and the study
by Ran et al. [6]. In the latter, no patients with diabetic
nephropathy on hemodialysis were included, whereas all
patients were free of cardiovascular complications. Our
results are in agreement with the study by von Eynatten
et al. where circulating adiponectin was not a predictor
of cIMT in subjects with early stage diabetic nephropathy
[47]. Similarly with adiponectin, ox-LDL was not associ-
ated with cIMT in the studied population, although cIMT
increased with disease staging and ox-LDL decreased. Since
there was an effect of statins on cIMT, we included statin
treatment in multiple regression analysis for cIMT along
with age, sex, eGFR, and HDL-cholesterol. However, only
sex and eGFR were significant predictors of cIMT in these
patients.
Clustering techniques are used when the data are
expected to group physically in various categories. Clus-
ter analysis was used to describe the patterns of diabetic
nephropathy based on the clinical, pathogenetic, and physio-
logical features. According to this analysis, four clusters were
formed, each one distinctively characterizing each stage of
diabetic nephropathy. Patients with the highest cIMT values,
highest levels of adiponectin, and lowest levels of ox-LDL
were included in one cluster and all assigned to stage 5
of diabetic nephropathy. Definitely, the repeatability of the
cluster solutions should be validated in different samples and
the clinical benefit must be proven [33]. Although cluster
analysis is inadequate in identifying disease causes, its results
may give insights into the structure of a data set and lead
to hypotheses for further investigation. In patients with
end stage diabetic nephropathy, the increased atherosclerotic
burden is peculiarly accompanied by a favorable profile
of both adiponectin and ox-LDL. Therefore, apart from
physiological and traditional factors associated with cIMT,
other pathological/protective factors affecting this surrogate
marker of atherosclerosis should be explored in diabetic
nephropathy. For example, other modified forms of LDL as
well as circulating markers of antioxidant capacity should be
examined since the latter have been shown to be negative
determinants of cIMT in diabetic patients [48].
To our knowledge, this is the first study assessing the
interrelationship of adiponectin and ox-LDL as well as
their effect on cIMT in diabetic nephropathy. However,
there are certain limitations in the present study. The
cross-sectional design of the study precludes establishing
causality. The number of patients with diabetic nephropa-
thy according to disease staging is small to draw definite
conclusions on the associations examined. Finally, only total
adiponectinwasmeasured and not its various isoformswhich
could show different associations with the variables exam-
ined.
5. Conclusions
An inverse association between circulating adiponectin and
ox-LDL was observed in diabetic nephropathy, whereas
adiponectin was an independent negative predictor of ox-
LDL in these patients. There was no significant association
between cIMT and adiponectin or ox-LDL either in the total
sample population or according to disease staging. Other
factors affecting this surrogate marker of cardiovascular dis-
ease in diabetic nephropathy should be sought in prospective
studies since the early detection of atherosclerotic changes
using biomarkers could reduce adverse outcomes.
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